Oculis and EURETINA Collaborate on a Meaningful Award
Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) has embarked on an inspiring journey by collaborating with EURETINA to announce the prestigious Ramin Tadayoni Award for 2025. This award is dedicated to honoring the memory of Professor Ramin Tadayoni, an immensely respected retina specialist and the Company’s Chief Scientific Officer. His untimely passing in 2024 left a significant void in the retina community, and this award aims to carry forward his legacy.
Recognizing Innovation in Retinal Research
The Ramin Tadayoni Award is set to play a pivotal role in the realm of ophthalmology. With an annual grant of €30,000 available for research, plus an additional €5,000 for the award recipient, it underscores Oculis' commitment to fostering innovative approaches in retinal disease treatment. The award seeks to motivate exceptional postgraduate scholars and encourage groundbreaking research that can transform understanding and treatment of retinal disorders.
Application Process and Announcement Details
For those aspiring to apply, submissions will be accepted until May 12, 2025. This award will be presented during the opening ceremony of the EURETINA Congress in Paris from September 4 to September 7, 2025. This event offers an excellent platform to highlight the critical advancements and future possibilities in retinal research.
Remembering Professor Tadayoni
CEO Riad Sherif, M.D. expressed his heartfelt sentiments regarding the award: “As we approach a year since Prof. Tadayoni's departure, it is a great honor to maintain our commitment to this award. His influence on the field and our plans at Oculis remains profound. This initiative embodies his unwavering enthusiasm for scientific progress and education, inspiring both current and future generations of ophthalmologists.”
A Tribute to a Visionary Leader
Anat Loewenstein, M.D., President of EURETINA, celebrated the continuation of this award, capturing Prof. Tadayoni’s influence not only as a scientist but also as a mentor. Their collaboration to uphold Tadayoni’s vision reinforces the values of excellence and innovation in retinal research, while simultaneously promoting burgeoning leaders in the field.
Previous Recipient Highlights
In 2024, Dr. Andrea Govetto, M.D., Ph.D. was honored as the inaugural laureate of the Ramin Tadayoni Award. Based at the Oftalmico-Fatebenefratelli Hospital in Milan, Italy, Dr. Govetto is conducting pivotal work focused on fluid dynamics and retinal tissue in macular edema, exemplifying the kind of transformative research the award is designed to promote.
Oculis: Pioneering Eye Care Innovations
Oculis positions itself as a dynamic force within the biopharmaceutical landscape, dedicated to enhancing eye care and striving toward groundbreaking solutions. The organization's innovative pipeline includes several promising candidates in clinical stages, such as OCS-01 for diabetic macular edema, OCS-05 focused on neuroprotection for optic neuritis, and OCS-02, a topical biologic aimed at treating dry eye disease.
Global Presence and Commitment
With headquarters in Switzerland and operations extending to the U.S. and Iceland, Oculis is supported by a robust management team and esteemed international healthcare investors. Their vision is clear: to pave new paths in the field of ophthalmology, ensuring improved outcomes for patients with vision-impairing conditions.
Frequently Asked Questions
What is the Ramin Tadayoni Award?
The Ramin Tadayoni Award is an annual award promoting innovative research in retinal diseases, honoring the legacy of Professor Ramin Tadayoni.
Who is eligible to apply for the Ramin Tadayoni Award?
The award is aimed at exceptional postgraduate scholars focused on retinal research. Applications can be submitted until May 12, 2025.
How much funding does the Ramin Tadayoni Award provide?
The award offers €30,000 for research support, plus an additional €5,000 for the recipient.
Where and when will the award be announced?
The award will be presented during the EURETINA Congress opening ceremony in Paris, scheduled for September 4-7, 2025.
What innovative research is Oculis currently pursuing?
Oculis is developing a pipeline of innovative products, including topical treatments for diabetic macular edema and dry eye disease, aimed at significantly improving patient care.
